Opioid resistance in chronic daily headache: A synthesis of ideas from the bench and bedside

Current Pain and Headache Reports

Volumn 7, Issue 1, 2003, Pages 67-75

  Biondi, David M ^a  

^a and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BUTALBITAL; CAFFEINE; DIHYDROERGOTAMINE; ERGOT DERIVATIVE; KETOROLAC; LONG ACTING DRUG; MORPHINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; SEROTONIN 1 AGONIST;

CHRONIC PAIN; COMORBIDITY; DISABILITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG TOLERANCE; DRUG USE; HEADACHE; HUMAN; HYPERALGESIA; MENTAL DISEASE; MIGRAINE; NERVE CELL PLASTICITY; NEUROPATHIC PAIN; PATHOPHYSIOLOGY; REVIEW; TENSION HEADACHE; CLINICAL TRIAL; DOSE RESPONSE; HEADACHE AND FACIAL PAIN; TREATMENT FAILURE;

ANALGESICS, OPIOID; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; HEADACHE DISORDERS; HUMANS; TREATMENT FAILURE;

EID: 0037318163     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-003-0013-5     Document Type: Review

References (90)

1. Scher AI, Stewart WF, Liberman J, et al.: Prevalence of frequent headache in a population sample. Headache 1998, 38:497-506.
2. Linton-Dahlof P, Linde M, Dahlof C: Withdrawal therapy improves chronic daily headache associated with long-term misuse of headache medication: a retrospective study. Cephalalgia 2000, 20:658-662.
3. Fritsche G, Eberl A, Katasarava Z, et al.: Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol 2001, 45:229-235.
4. Pini LA, Cicero AF, Sandrini M: Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia 2001, 21:878-883.
5. Saper JR: From the role of chronic opioid therapy in managing chronic daily headache: a roundtable discussion. Presented at the Annual Scientific Meeting of the American Headache Society. Seattle, WA; 2002.
6. Rothrock J. From The role of chronic opioid therapy in managing chronic daily headache: a roundtable discussion. Presented at the Annual Scientific Meeting of the American Headache Society. Seattle, WA; 2002.
7. Zimmermann M: Pathobiology of neuropathic pain. Eur J Pharmacol 2001, 429:23-37.
8. Silberstein SD, Lipton RB, Sliwinski M: Classification of daily or near-daily headaches: a field study of the revised IHS criteria. Neurology 1996, 47:871-875.
9. Silberstein SD, Lipton RB, Solomon S, et al.: Classification of daily and near-daily headaches: proposed revisions to the IHS criteria. Headache 1994, 34:1-7.
10. Olesen J: Revision of the International Headache Classification: an interim report. Cephalalgia 2001, 21:261.
11. Mathew NT, Stubits E, Nigam M: Transformation of migraine into daily headache: analysis of factors. Headache 1982, 22:66-68.
12. Vingen JV, Sand T, Stover LJ: Sensitivity to various stimuli in primary headaches: a questionnaire study. Headache 1999, 39:552-558.
13. Bahra A, Walsh M, Menon S, Goadsby PJ: Does chronic daily headache arise de novo in association with regular analgesic use? [Abstract]. Cephalalgia 2000, 20:294.
14. Lance F, Parkes C, Wilkinson M: Does analgesic abuse cause headache de novo? Headache 1988, 38:61-62.
15. Wilkinson SM, Becker WJ, Heine JA: Opiate use to control bowel motility may induce chronic headache in patients with migraine. Headache 2001, 41:303-309.
16. Rapoport AM, Stang P, Gutterman DL, et al.: Analgesic rebound headache in clinical practice: data from a physician survey. Headache 1996, 36:14-19.
17. Rapoport AM: Analgesic rebound headache. Headache 1988, 28:662-665.
18. Solomon S, Lipton RB, Newman LC: Clinical features of chronic daily headache. Headache 1992, 32:325-329.
19. Scher A, Stewart WF, Liberman J, et al.: Prevalence of frequent headache in a population sample. Headache 1998, 38:497-506.
20. Castillo J, Munoz P, Guitera V, et al.: Epidemiology of chronic daily headache in the general population. Headache 1999, 39:190-196.
21. Granella F, Farina S, Malferrani G, et al.: Drug abuse in chronic headache: a clinico-epidemiologic study. Cephalalgia 1987, 7:15-19.
22. Ravishankar K: Headache pattern in India-a headache clinic analysis of 1000 patients [abstract]. Cephalalgia 1997, 17:316-317.
23. Diener HC, Dahlof CGH: Headache associated with chronic use of substances. In The Headaches, edn 2. Edited by Olesen J, Tfelt-Hansen P, Welsh KMA. Philadelphia: Lippincott Williams & Wilkins; 2000:871-878.
24. Baumgartner C, Wessely P, Bingol C, et al.: Long-term prognosis of analgesic withdrawal in patients with drug-induced headache. Headache 1989, 29:510-514.
25. Schneider P, Aull S, Baumgartner C, et al.: Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five year follow-up. Cephalalgia 1996, 16:481-485.
26. Diener HC, Dichgans J, Scholz E, et al.: Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 1989, 236:9-14.
27. Zed PJ, Loewen PS, Robinson G: Medication-induced headache: overview and systematic review of therapeutic approaches. Ann Pharmacother 1999, 33:61-72.
28. Tepper SJ, Dodick DW: Debate: analgesic overuse is a cause, not consequence of chronic daily headache. Headache 2002, 42:543-554.
29. Williamson DJ, Hargreaves RJ: Neurogenic inflammation in the context of migraine. Microsc Res Tech 2001, 53:167-178.
30. Aurora SK: Pathophysiology of migraine headache. Curr Pain Headache Rep 2001, 5:179-182.
31. Edvisson L: Pathophysiology of primary headaches. Curr Pain Headache Rep 2001, 5:71-78.
32. Burstein R, Yarnitsky D, Goor-Aryeh I, et al.: An association between migraine and cutaneous allodynia. Ann Neurol 2000, 47:614-624.
33. Burstein R, Cutrer FM, Yarnitsky D: The development of cutaneous allodynia during a migraine attack: clinical evidence for sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000, 123:1703-1709.
34. Silberstein SD: Tension-type headache and chronic daily headache. Neurology 1993, 43:1644-1649.
35. Welsh KMA, Goadsby PJ: Chronic daily headache. Curr Opin Neurol 2002, 15:287-295.
36. Sandrini G, Antonaci F, Pucci E: Comparative study with EMG, pressure algometry, and manual palpation in tension-type headache and migraine. Cephalalgia 1994, 14:451-457.
37. Jensen R, Olesen J: Initiating mechanisms of experimentally induced tension-type headache. Cephalalgia 1996, 16:175-182.
38. Bendtsen L, Ashina M: Sensitization of myofascial pain pathways in tension-type headache. In The Headaches, edn 2. Edited by Oleson J, Tfelt-Hansen P, Welsh KMA. Philadelphia: Lippincott Williams & Wilkins; 2000:573-577.
39. Moskowitz MA: The neurobiology of vascular head pain. Ann Neurol 1984, 15:157-168.
40. Srikiatkhachorn A: Pathophysiology of chronic daily headache. Curr Pain Headache Rep 2001, 5:537-544.
41. Ji RR, Woolf CJ: Neuronal plasticity and spinal transduction in nociceptive neurons: implication for the initiation and maintenance of pathologic pain. Neurobiol Dis 2001, 8:1-10.
42. Clifford DB, Zorumski CF, Olney JW: Ketamine and MK-801 prevent degeneration of thalamic neurons induced by focal cortical seizures. Exp Neurol 1989, 105:272-279.
43. Grewal SS, York RD, Stork PJS: Extracellular-signal-regulated kinase signaling in neurons. Curr Opin Neurol 1999, 9:544-553.
44. Ahlemeyer B, Kolker S, Zhu Y, et al.: Increase in glutamate-induced neurotoxicity by activated astrocytes involves stimulation of protein kinase C. J Neurochem 2002, 82:504-515.
45. Cardell M, Wieloch T: Time course of the translocation and inhibition of protein kinase C during complete cerebral ischemia in the rat. J Neurochem 1993, 61:1308-1314.
46. Strubos PJLM: Nitric oxide in cerebral ischemia, neurodegeneration and excitotoxicity. Crit Rev Neurobiol 1998, 12:223-243.
47. Urushitani M, Shimohama S: The role of nitric oxide in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2001, 2:71-81.
48. Ashina M, Bendtsen L, Jensen R, et al.: Nitric oxide-induced headache in patients with chronic tension-type headache. Brain 2000, 123:1830-1837.
49. Welsh KMA, Nagesh V, Aurora S, et al.: Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001, 41:629-637.
50. Gutstein HB, Akil H: Opioid analgesics. In Goodman and Gilman's: The Pharmacologic Basis of Therapeutics, edn 10. Edited by Hardman JG, Limbard LE. New York: McGraw Hill; 2001:569-619.
51. Planas ME, Rodriquez L, Sanchez S, et al.: Pharmacologic evidence for the involvement of the endogenous opioid system in the response to local inflammation in the rat paw. Pain 1995, 60:67-71.
52. Williamson DJ, Shepheard SL, Cook DA, et al.: Role of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurons in anesthetized rats. Br J Pharmacol 2001, 133:807-814.
53. Arner S, Meyerson BA: Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988, 33:11-23.
54. Benedetti F, Vighetti S, Amanzio M, et al.: Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain 1998, 74:205-211.
55. Attal N, Guirimand F, Brasseur L, et al.: Effects of IV morphine in central pain. Neurology 2002, 58:554-563.
56. Ossipov MH, Lopez Y, Nichols ML, et al.: The loss of antinociceptive efficacy of spinal morphine in rats with nerve ligation injury is prevented by reducing spinal afferent drive. Neurosci Lett 1995, 199:87-90.
57. Dellemijn P: Are opioids effective in relieving neuropathic pain? Pain 1999, 80:453-462.
58. Rowbotham MC, Reisner-Keller LA, Fields HL: Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991, 41:1024-1028.
59. Portnoy RK, Hagen NA: Breakthrough pain: definition, prevalence, and characteristics. Pain 1990, 41:273-281.
60. Mao J, Price DD, Mayer DJ: Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994, 14:2301-2312.
61. Celerier E, Laulin JP, Corcuff JB, et al.: Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci 2001, 21:4074-4080.
62. Devulder J: Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. J Neurosurg Anesthesiol 1997, 9:146-148.
63. Sjogren P, Josson T, Jesen NH, et al.: Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993, 55:93-97.
64. Silberstein SD: Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55:754-762.
65. Carleton SC, Shesser RF, Pietrzak MP, et al.: Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache. Ann Emerg Med 1998, 32:129-138.
66. Larkin GL, Prescott JE: A randomized, double-blind comparative study of the efficacy of ketorolac tromethanine versus meperidine in the treatment of severe migraine. Ann Emerg Med 1992, 21:919-924.
67. Sicuteri F: Opioid receptor impairment underlying mechanism in "pain diseases"? Cephalalgia 1981, 1:77-82.
68. Panconesi A, Anselmi B, Franchi G: Increased adverse effects of opiates in migraine patients. Cephalalgia 1995, 15:159-160.
69. Pini LA, Sandrini M, Vital, G: The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain. Eur J Pharmacol 1996, 308:31-40.
70. Bjorkman R: Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol: experimental studies in the rat. Acta Anaesthesiol Scand 1995, 39 (suppl 103):1-44.
71. Srikiatkhachorn A, Anthony M: Platelet serotonin in patients with analgesic induced headache. Cephalalgia 1996, 16:423-426.
72. Srikiatkhachorn A, Manseesri S, Govitrapong P, et al.: Derangement of serotonin system in migraine patients with analgesic abuse headache: clues from the platelets. Headache 1998, 38:43-49.
73. Hering R, Glover V, Pattichis K, et al.: 5HT in migraine patients with medication- induced headaches. Cephalalgia 1993, 13:410-412.
74. Sarchelli P, Alberti A, Russo S, et al.: Nitric oxide pathway, Ca2+ and serotonin content in platelets from patients suffering from chronic daily headache. Cephalalgia 1999, 19:810-816.
75. Srikiatkhachorn A, Anuntasethakul T, Manseesri S, et al.: Hyposerotonin-induced nitric oxide supersensitivity in the cerebral microcirculation. Headache 2000, 40:267-275.
76. Srikiatkhachorn A, Tarasub N, Govitrapong P: Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. Headache 2000, 40:343-350.
77. Carruba MO, Nisoli E, Garosi V, et al.: Catecholamine and serotonin depletion from rat spinal cord: effects on morphine and footshock-induced analgesia. Pharmacol Res 1992, 25:187-194.
78. Martinez F, Castillo J, Pardo J, et al.: Catecholamine levels in plasma and CSF in migraine. J Neurol Neurosurg Psychiatry 1993, 56:1119-1121.
79. Jhamandas KH, Powell KJ, Quirion R, et al.: Opioid tolerance and physical dependence: role of spinal neuropeptides, excitatory amino acids, and their messengers. Pain Res Manage 2000, 5:25-32.
80. Chen L, Huang LYM: Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a mu-opioid. Neuron 1991, 7:319-326.
81. Mao J, Mayer DJ: Spinal cord neuroplasticity following repeated opioid exposure and its relation to pathologic pain. Ann NY Acad Sci 2001, 933:175-184.
82. Trang T, Sutak M, Quirion R, et al.: The role of spinal neuropeptides and prostaglandins in opioid physical dependence. Br J Pharmacol 2002, 136:37-48.
83. Mao J, Sung B, Ji R, et al.: Chronic morphine induces down regulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 2002, 22:8312-8323.
84. Ozawa T, Nakagawa T, Shige K, et al.: Changes in the expression of glial glutamate transporters in the rat brain accompanied with morphine dependence and naloxone-precipitated withdrawal. Brain Res 2001, 905:254-258.
85. He L, Fong J, VonZastrow M, et al.: Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 2002, 108:271-282:
86. Machelska H, Ziolkowska B, Mika J, et al.: Chronic morphine increases biosynthesis of nitric oxide synthase in the rat spinal cord. Neuroreport 1997, 8:2743-2747.
87. Przewlocki R, Przewlocka B: Opioids in chronic pain. Eur J Pharmacol 2001, 429:79-91.
88. Kieffer BL, Evans CJ: Opioid tolerance-in search of the Holy Grail. Cell 2002, 108:587-590.
89. Mao J, Price DD, Mayer DJ: Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and hyperalgesia. Pain 1995, 61:353-364.
90. Mao J, Sung B, Ru-Rong J, et al.: Neuronal apoptosis associated with morphine tolerance: evidence for an opioid-induced neurotoxic mechanism. J Neurosci 2002, 22:7650-7661.